Rivastigmine for dementia associated with Parkinson's disease

Curr Neurol Neurosci Rep. 2005 Jul;5(4):263-5. doi: 10.1007/s11910-005-0070-8.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / adverse effects
  • Dementia / drug therapy*
  • Dementia / etiology*
  • Dementia / physiopathology
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Mental Disorders / etiology
  • Middle Aged
  • Nausea / chemically induced
  • Neuroprotective Agents / administration & dosage*
  • Neuroprotective Agents / adverse effects*
  • Parkinson Disease / complications*
  • Patient Selection
  • Phenylcarbamates / administration & dosage*
  • Phenylcarbamates / adverse effects*
  • Prospective Studies
  • Rivastigmine
  • Treatment Outcome
  • Tremor / chemically induced
  • Tremor / physiopathology
  • Vomiting / chemically induced

Substances

  • Cholinesterase Inhibitors
  • Neuroprotective Agents
  • Phenylcarbamates
  • Rivastigmine